Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common arthritis drug tame recurring eye inflammation?

NCT ID NCT03020992

Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether certolizumab pegol (Cimzia), a drug already used for arthritis, can reduce flares of anterior uveitis—a painful eye inflammation—in people with axial spondyloarthritis who have had uveitis before. About 89 adults with active axial spondyloarthritis and a history of uveitis will receive the drug and be monitored for new eye inflammation episodes over 48 weeks. The goal is to see if the drug can prevent or reduce these flares.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
certolizumab pegol (Cimzia)
What this could lead to
If it works, this could offer a way to reduce painful eye inflammation flares in people with axial spondyloarthritis.
What could go wrong
This is a small, open-label study without a placebo group, so results may be less reliable. The drug may not work for everyone and carries risks like infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

89 people

The number who actually took part.

Started

Dec 2016

Finished

Jan 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects must have a documented diagnosis of adult-onset axial Spondyloarthritis (axSpA) with at least 3 months' symptom duration and meet the Assessment of SpondyloArthritis International Society (ASAS) criteria * Subjects must have active disease at Screening as defined by * Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score \>= 4 * Spinal pain \>= 4 on a 0 to 10 Numerical Rating Scale (NRS; from BASDAI item 2) * Nonradiographic (Nr)-axSpA subjects must either have C-reactive protein (CRP) \> upper limit of normal (ULN) and /or current evidence of sacroiliitis on magnetic resonance imaging (MRI) (no confirmation by central reading) as defined by ASAS criteria * Ankylosing spondylitis (AS) subjects must have evidence of sacroiliitis on x-ray meeting the modified New York (mNY) classification criteria according to the Investigator * Subjects must have a documented history of Anterior Uveitis (AU) diagnosed by an ophthalmologist and have at least 2 AU flares in the past, of which at least 1 AU flare was in the last 12 months prior to Baseline Exclusion Criteria: * Other inflammatory arthritis * Secondary, noninflammatory condition that, in the Investigator's opinion, is symptomatic enough to interfere with evaluation of the effect of study drug on the subject's primary diagnosis of axial spondyloarthritis (axSpA) * Any history of uveitis except for Anterior Uveitis (AU) associated with axSpA * Any condition or complicating factor that may interfere with the AU assessment * Retisert® or Iluvien® (glucocorticosteroid implant) within 3 years prior to the Baseline Visit or has had complications related to the device * Subject has had Retisert or Iluvien (glucocorticosteroid implant) removed within 90 days prior to the Baseline Visit * Intraocular or periocular corticosteroids within 90 days prior to the Baseline visit * Ozurdex® (dexamethasone implant) within 6 months prior to the Baseline Visit * Cyclophosphamide within 30 days prior to the Baseline Visit * Intravitreal methotrexate (MTX) within 90 days prior to the Baseline Visit * Intravitreal anti-vascular endothelial growth factor (VEGF) therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anterior uveitis (AU) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anterior uveitis Axial Spondyloarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anterior uveitis (AU) Axial spondyloarthritis (axspa)

Contacts and locations

Locations

  • As0007 101

    Brno, Czechia

  • As0007 102

    Prague, Czechia

  • As0007 103

    Brno, Czechia

  • As0007 105

    Prague, Czechia

  • As0007 107

    Brno, Czechia

  • As0007 108

    Ostrava, Czechia

  • As0007 109

    Pardubice, Czechia

  • As0007 301

    Freiburg im Breisgau, Germany

  • As0007 302

    München, Germany

  • As0007 303

    Münster, Germany

  • As0007 401

    Amsterdam, Netherlands

  • As0007 501

    Warsaw, Poland

  • As0007 502

    Torun, Poland

  • As0007 504

    Wroclaw, Poland

  • As0007 505

    Warsaw, Poland

  • As0007 506

    Bialystok, Poland

  • As0007 507

    Wroclaw, Poland

  • As0007 508

    Wroclaw, Poland

  • As0007 509

    Poznan, Poland

  • As0007 510

    Lublin, Poland

  • As0007 511

    Poznan, Poland

  • As0007 601

    Córdoba, Spain

  • As0007 604

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.